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Abstract
Background: All patients who undergo surgery for colon cancer are followed up according to the
guidelines of the Norwegian Gastrointestinal Cancer Group (NGICG). These guidelines state that
the aims of follow-up after surgery are to perform quality assessment, provide support and improve
survival. In Norway, most of these patients are followed up in a hospital setting. We describe a
multi-centre randomized controlled trial to test whether these patients can be followed up by their
general practitioner (GP) without altering quality of life, cost effectiveness and/or the incidence of
serious clinical events.
Methods and Design: Patients undergoing surgery for colon cancer with histological grade
Dukes's Stage A, B or C and below 75 years of age are eligible for inclusion. They will be
randomized after surgery to follow-up at the surgical outpatient clinic (control group) or follow-
up by the district GP (intervention group). Both study arms comply with the national NGICG
guidelines. The primary endpoints will be quality of life (QoL) (measured by the EORTC QLQ C-
30 and the EQ-5D instruments), serious clinical events (SCEs), and costs. The follow-up period will
be two years after surgery, and quality of life will be measured every three months. SCEs and costs
will be estimated prospectively. The sample size was 170 patients.
Discussion: There is an ongoing debate on the best method of follow-up for patients with CRC.
Due to a wide range of follow-up programmes and paucity of randomized trials, it is impossible to
draw conclusions about the best combination and frequency of clinic (or family practice) visits,
blood tests, endoscopic procedures and radiological examinations that maximize the clinical
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outcome, quality of life and costs. Most studies on follow-up of CRC patients have been performed
in a hospital outpatient setting. We hypothesize that postoperative follow-up of colon cancer
patients (according to national guidelines) by GPs will not have any impact on patients' quality of
life. Furthermore, we hypothesize that there will be no increase in SCEs and that the incremental
cost-effectiveness ratio will improve.
Trial registration: This trial has been registered at ClinicalTrials.gov. The trial registration
number is: NCT00572143
Background
An increasing incidence of colorectal cancer (CRC) has
been observed in Norway during the past decades. Accord-
ing to the Cancer Registry of Norway, 2296 new cases of
colon cancer were reported in 2006, making the disease
among the most common type of cancer in both genders.
The incidence in Norway is significantly higher than in the
other Nordic countries [1]. The background for this dis-
crepancy is unknown [2]. The overall five-year survival
rate in 1993–97 was 56% for males and 60% for females
[3]. At the time of diagnosis, about two thirds of patients
had undergone resection, but 30–50% of them relapsed
and died of the disease [4].
There is an ongoing debate on the best follow-up regimen
for patients with CRC [5-7]. A meta-analysis published in
2002, including 1342 patients, demonstrated that inten-
sive follow-up in CRC was associated with an absolute
reduction in 5-year all-cause mortality of 10% [8]. Other
trials have revealed similar results [9]. Due to the wide
range of follow-up programmes employed, it is impossi-
ble to draw conclusions on the best combination and fre-
quency of clinic visits, blood tests, endoscopic procedures,
and radiological examinations that maximize the clinical
outcome. Furthermore, the potential harms and costs of
an intensified follow-up programme have not been clari-
fied. The Norwegian Gastrointestinal Cancer Group
(NGICG) revised its follow-up guidelines (Table 1) in
2007 [10]. According to these guidelines, most of the fol-
low-up can be done by GPs. The aims of the follow-up
programme are to perform quality assessment, provide
support and improve survival. Most relapses (80%) of
colon cancer are detected within the first three years of fol-
low-up [11]. Based on this knowledge, the regular check-
ups are recommended at three- month intervals for the
first two years and then every six months. A similar CRC
surveillance guideline was presented in 2005 by the Amer-
ican Society of Clinical Oncology (ASCO) [12].
During recent years, several critical articles have been pub-
lished arguing against present follow-up procedures. So
far, most studies addressing follow-up of CRC patients
have been performed in a hospital setting. According to a
recent Cochrane review, further research is needed, focus-
ing on follow-up schedules in either a hospital setting or
in general practice [6]. Whereas systematic postoperative
surveillance has been extensively studied with regard to
cure and survival, the possible benefits in terms of
improved palliative care and/or quality of life have been
less widely documented.
The purpose of this study is to obtain insight into quality
of life among colon cancer patients followed up in a hos-
pital outpatient setting or by their GPs and into the incre-
mental cost-effectiveness ratio from the point of view of
health care and of society.
Methods and Design
Study design
This trial is a multi-centre randomized controlled study
where patients will either be randomized to follow-up at
Table 1: Follow-up of patients with colon cancer as proposed by the Norwegian Gastrointestinal Cancer Group (NGICG).
Examination Months postoperative
13691 21 51 82 1 2 43 03 64 24 85 46 0
C h e s t  x - r a y X XX XXXX
Ultrasound liver X X X X X X X
Coloscopy X X
CEA measurementa X X X X XXXX XXXXXXX
Clinical examination X X X X X X X X X X XXXXX
This guideline is employed at Norwegian hospitals and will be used in both trial arms.
aOnly patients with elevated CEA prior to surgery are requested to undergo this test during the follow-up.BMC Health Services Research 2008, 8:137 http://www.biomedcentral.com/1472-6963/8/137
Page 3 of 8
(page number not for citation purposes)
the hospital (control group) or by their GP (intervention
group) (Figure 1).
Participants
Patients
Patients are eligible if they undergo surgery for colon can-
cer with histological grade Dukes's Stage A, B or C.
Patients receiving postsurgical adjuvant chemotherapy
(Dukes C) are also eligible. We define a colon cancer as a
tumour located 15 cm above the anal verge by coloscopy
or a tumour at or above the level of the sacral promontory
as seen at the time of surgery. Annually, approximately
200 patients with colon cancer undergo surgery in the
catchment area of the North Norwegian Hospital Trust (a
population of 470,000).
Hospitals
There are three hospital trusts and one university hospital
(UNN HF) (in total 11 hospital units) located within the
North-Norwegian Health Region. Three hospitals (located
in the cities of Harstad, Mo, and Bodø) have an annual
volume of more than 20 colon cancer procedures; the
University Hospital operates on about 110 patients with
suspected CRC cancer annually and approximately 60 of
them have a colon cancer disclosed. The University Hos-
pital and these three local hospitals consented to partici-
pate. All patients who undergo surgery for colon cancer
are followed up at the surgical outpatient clinic at each
hospital.
Trial Flow Chart Figure 1
Trial Flow Chart
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GPs
In North Norway, 550 GPs refer patients with suspected
colon cancer to the local hospitals. They are situated in all
communities in North Norway. All GPs were informed by
mail about the purpose of the study and invited to partic-
ipate. None refused to participate.
Intervention
Patients are randomized to follow-up either by their GP
(intervention) or at the surgical outpatient clinic. All
patients will receive their first postoperative check-up at
the hospital which performed the surgery (baseline, 1
month). A clinical examination will then be performed
and information about the histology and the results of the
surgery will be provided. If the patient gives informed
consent, randomization is performed. Patients rand-
omized to GP follow-up are referred to their GP. This
referral contains information about the surgery and any
complications, Dukes's staging, guidelines for follow-up
and behavioural strategy in the case of a SCE.
Guidelines for follow-up
NGICG revised its guidelines in 2007 [10] (Table 1), and
the GPs were provided with a guideline form based upon
this recommendation. Most relapses of colon cancer are
detected within the first three years of follow-up. On the
basis of this knowledge, the regular check-ups are per-
formed at three-month intervals for the first two years and
then every six months.
All patients with elevated CEA prior to surgery are
requested to undergo this test at every postoperative clin-
ical examination. Chest x-ray and ultrasound are per-
formed on a regular basis. Colonoscopy is performed
twice during the follow-up period. The follow-up guide-
line is similar in both arms (Table 1).
When recurrence is suspected
All GPs are given written instructions on what to do if
recurrence is suspected. A set of serious clinical events
(SCEs) is defined as: Colonoscopy verifies recurrence of
CRC. Elevated levels of CEA are shown by repeated meas-
urements. Blood in stool is detected by the Hemofec test.
Unexplained abdominal pain. Unexplained weight loss of
5 kg during the last three months. Cancer-suspect lesions
detected by rectal examination. Lymphandenopathy.
Metastasis-suspect lesions shown by chest x-ray or ultra-
sound of liver. If an SCE occurs, the patient must be
referred promptly to hospital.
Information to the patient
All patients included in the study are given a folder
explaining the purpose of the study. Follow-up guidelines
are provided with detailed information concerning the
clinical examinations, CEA measurements, x-ray/ultra-
sound procedures and colonoscopy.
QOL questionnaires
The EQ-5D and EORTC-QLQ C30 questionnaires for the
two-year follow-up period (at 1, 3, 6, 9, 12, 15, 18, 21, 24
month follow-up) are given to the patient at baseline
examination.
Economic evaluation questionnaire: A questionnaire has
been developed to enable calculation of costs related to
patient examinations. This questionnaire is incorporated
in the QOL questionnaire, and patients are requested to
fill out the questionnaire at 1, 3 6, 9, 12, 15, 18, 21 and 24
months postoperatively. The cost elements will include
patient- and family-related costs due to outpatient visits,
GP visits, laboratory tests, radiographs/ultrasound, exam-
inations due to suspected relapse, treatment of relapse,
travelling, production losses, co-payments and other
patient expenses.
Control arm
Patients in the control group consist of patients rand-
omized to regular follow-up at the hospital's surgical out-
patient clinic. All these patients are followed up according
to the NGICG guidelines. This follow-up is performed by
consultants or internship doctors in digestive surgery.
Objectives
Primary objective
We aim to compare quality of life and costs of follow-up
among patients followed up by their local GP or at the sur-
gical outpatient clinic. We hypothesize that patients fol-
lowed up by their GP will experience similar or higher
scores on quality of life measures and lower costs during
follow-up.
Secondary objective
We aim to test whether the incidence of SCEs will be sim-
ilar for patients followed up by their GP and patients in
the control group. We hypothesize that patients followed
up by their GP will not have an increase in time to detec-
tion or in the frequency of SCEs.
Outcome measures
Primary outcome (measured at 1, 3, 6,9,12,15,18,21 and 24 
months)
Quality of life
EQ-5D is a standardized generic instrument for use as a
measure of health outcome. Applicable to a wide range of
health conditions and treatments, it provides a simple
descriptive profile and a single index value for health sta-
tus. EQ-5D measures five dimensions of health-related
quality of life (HRQOL): mobility, self-care, usual activi-
ties, pain/discomfort and anxiety/depression. EQ VisualBMC Health Services Research 2008, 8:137 http://www.biomedcentral.com/1472-6963/8/137
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Analogue Scale: The EQ VAS records the respondent's self-
rated health status on a vertically graduated (0–100) vis-
ual analogue scale [13]. Quality of life assessment based
upon the European Organization for Research and Treat-
ment of Cancer Quality of Life questionnaire (EORTC
QLQ C-30); EORTC QLQ C-30 incorporates nine multi-
item scales: five functional scales (physical, role, cogni-
tive, emotional and social); three symptom scales
(fatigue, pain, nausea/vomiting); and a global health sta-
tus/QOL scale. Six single-item scales are also included
(dyspnoea, insomnia, appetite loss, constipation, diar-
rhoea and financial difficulties) [14].
Economic analysis
A cost-effectiveness analysis will be performed alongside
the randomized controlled trial. A Markov model will be
employed. If the trial reveals no difference in health out-
comes or quality of life of the patients, a cost-minimiza-
tion analysis will be carried out. If we reveal a difference
in quality of life between the two groups, we will imple-
ment a cost-utility analysis. The economic evaluation will
have a health care and societal perspective. Resources used
in both treatment arms will be registered prospectively
based on reports by the patients and on the hospital
patient records. Costs related to consultations at the pri-
mary and secondary care level, both at baseline and up to
24 months after randomization, including direct medical
costs, indirect costs (production losses), travel costs and
patient-/family-related costs will be registered. Quality of
life measurements will be collected both at baseline and
at several time points during the intervention. A 3% dis-
count rate will be used to discount future costs and bene-
fits. The cost elements will include costs related to
outpatient visits, GP visits, laboratory tests, radiographs/
ultrasound, examinations due to suspected relapse, treat-
ment of relapse, travelling/transportation, production
losses, co-payments and other patient/family expenses.
The net costs and outcomes of the two treatment options
will be compared and presented as incremental cost-effec-
tiveness ratios.
Secondary outcome measures
Serious clinical events (SCEs)
Time to detection of recurrences and serious clinical
events (SCEs) defined as: Colonoscopy-verified recur-
rence of cancer disease. Increase in CEA measurements
shown by repeated measurements. Blood in stool detected
by the Hemofec test. Unexplained abdominal pain. Unex-
plained weight loss of 5 kg during the last three months.
Cancer-suspect lesions detected in rectal examination.
Lymphandenopathy. Metastatic suspect lesions shown by
chest x-ray or ultrasound of liver.
Sample size
Sample size calculations are according to Campbell's
guidelines [15]
Alpha and beta were set at 0.05 and 0.2 respectively and
tests were two-sided. We hypothesize that patients fol-
lowed up by their GP will have a minor to moderate
increase in the Global QoL scores (EORTOC-QLQ C30).
This moderate effect size equals an increase of 10 units on
the Global QOL [16]. Patients with colon cancer (local
disease) show a standard deviation of approximately 20
(global QOL) [16]. Allowing for a dropout rate of 20%, to
detect this difference with confidence we required a total
sample size of 170 patients. Sample size calculations
based upon EQ-5D showed similar results [17].
Randomization
Randomization will be done at the 1-month check-up
(baseline) after the patients have given informed consent.
The randomization service is web-based and managed by
the Norwegian University of Science and Technology.
Patients are stratified according to the Dukes's staging and
whether they have a stoma. Patients allocated to general
practice follow-up may be referred back to surgical clinics
at any point in the study; similarly, patients in the sur-
geon-led follow-up group are free to consult their GP at
any time during the study.
Data gathering
Data are being collected for patients in the intervention
and the control group in identical ways. QoL and "cost
questionnaires" are sent every three months (after each
follow-up appointment) by the patients to the trial centre
up to 24 months postoperatively. These questionnaires
are optically readable, data being consecutively collected
in a trial database.
SCEs are registered via hospital chart review at 24 months
postoperatively. This follow-up period will allow identifi-
cation of most SCEs, since tumour recurrence typically
occurs within two years of surgery [11].
The study has been approved by the Norwegian Data
Inspectorate. All data will be handled with strict confiden-
tiality, and study reports or presentations will maintain
the anonymity of patients, surgeons, GPs and hospitals.
Data collection will be complete by the end of 2010.
Analysis
We will use the intention-to-treat principle when analys-
ing data. Furthermore, we will employ Fayers guidelines
to handle missing data [18]. Treatment arms will be com-
pared with respect to potential covariates using continu-
ous and categorical univariable analyses. These will
include variables relating to patients (age, sex, comorbid-BMC Health Services Research 2008, 8:137 http://www.biomedcentral.com/1472-6963/8/137
Page 6 of 8
(page number not for citation purposes)
ities, cost), treatment (surgical resection, surgical compli-
cations, adjuvant therapy), tumour (Dukes's Stage),
hospital surgical outpatient clinic (cost, patient satisfac-
tion, QoL), GP practice (cost, patient satisfaction, QoL).
The cost elements will include costs related to outpatient
visits, GP visits, laboratory tests, radiographs/ultrasound,
and examinations due to suspected relapse, treatment of
relapse, travelling/transportation, production losses, co-
payments and other patient expenses. The net costs and
outcomes of the two treatment options will be compared
and presented as cost-effectiveness ratios. If the trial
reveals no difference in health outcomes or quality of life
for the patients, a cost-minimization analysis will be car-
ried out. If we find a difference in quality of life or overall
survival rates between the two groups, we will use a cost-
utility approach. The economic evaluation will have a
societal and health care perspective.
The method of analysis, including adjusting for covariates
will comply with the CONSORT statement [19]. The
results will be expressed as odds ratios for binary out-
comes, hazard ratios for time- to-event outcomes or mean
differences for continuous outcomes with corresponding
standard errors, 95% confidence intervals, and associated
p-values. P-values will be reported to three decimal places
with p-values less than 0.001 reported as p < 0.001. For all
tests we will use alpha = 0.05 level of significance.
Ethics
The Regional Committee for Medical Research Ethics,
North Norway approved this protocol (P REK NORD 79/
2006). Patients must provide written consent before
entering the trial.
Discussion
Whereas systematic postoperative surveillance has been
extensively studied with regard to cure and survival, the
possible benefit of surveillance with regard to better out-
come of palliative care and/or quality of life has been less
widely documented. It has been shown that follow-up
programmes can lead to psychological stress [20]. Kjeld-
sen concluded that patients receiving frequent follow-ups
had greater confidence in the check-ups, but the improve-
ment in the health-related quality of life was only margin-
ally improved. The study concludes that the minor
improvement in health-related quality of life does not jus-
tify an expensive and frequent follow-up schedule [21].
Kievit published a meta-analysis in 2002 arguing for an
increased focus on quality assessment and patient support
in a follow-up programme, as improved survival is real-
ized in only a few patients [22]. According to this study,
there is no need for routine follow-up to be performed by
a surgeon. Patients with asymptomatic but incurable dis-
ease (9% in Korners study) [23], raise serious ethical con-
cerns. Even with today's chemotherapy regimens with
significant effects in terms of response rate and overall sur-
vival, cure is rarely seen when patients are beyond salvage
curative surgery [24]. A meta-analysis of six randomized
trials demonstrated that intensive follow-up in colorectal
cancer was associated with an absolute reduction in all-
cause 5-year mortality of 10%; however, only two percent
was attributable to cure from salvage re-operations. Rene-
han et al postulate that other factors, such as increased
psychological well-being and/or altered lifestyle, and/or
improved treatment of coincidental disease may contrib-
ute to the remaining lives saved [25].
The geography of Norway makes the costs of travelling a
significant burden. In North Norway in particular, the
population is scattered throughout a large geographic
area, making the cost of travel to a specialist examination
considerable. The specialists are mainly located in a few
main cities. New regulations requiring each hospital to
cover travel expenses have resulted in a stronger focus on
these costs in recent years. At present, 5% of the total
budget of the Regional Health Authority of North Norway
is spent on travelling/transportation. The cost of travelling
was earlier funded by the Norwegian Insurance Adminis-
tration. If a follow-up programme (i.e. clinical examina-
tion and medical history) can be run by the patient's GP,
there are obvious reasons to believe that the total costs of
such a programme could be reduced.
Whereas there is evidence of survival gain related to inten-
sive follow-up programmes, the burden of cost to the
health care service is considerable [26-28]. Renehan et al.
published a study in 2004 arguing that intensive follow-
up after curative resection for colorectal cancer is econom-
ically justified and should be standard practice [29]. How-
ever, a Danish study concludes the opposite, stating that
follow-up after colorectal cancer surgery is not cost-effec-
tive compared to several other procedures, including
screening for CRC [21]. The cost-effectiveness of the Nor-
wegian guidelines was documented cost-effective in a
prior study when applied in a model-based study imple-
menting data from the literature. The basic cost of the
NGICG recommended programme was GBP£ 1,232 per
patient. Including extended investigation due to sus-
pected relapse in 45% of cases, the figure rose to £ 1,943
per patient [30]. However, Korner et al [23] argue against
this study. The total programme cost in this study was
Euro € 228,117 (US 280,994 dollars), translating into €
20,530 (US 25,289 dollars) for one surviving patient after
salvage surgery. This cost is less than the one calculated by
Norum, but the costs are calculated at different times and
in different settings, making a direct comparison useless.
Costs are hard to compare with publications from other
countries because of different reimbursement policies.
Finally, they [23] argue whether the continuing imple-BMC Health Services Research 2008, 8:137 http://www.biomedcentral.com/1472-6963/8/137
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mentation of such a program and costs are justified
should be further debated.
The setting of follow-up may have an impact on patients'
well-being and satisfaction with care. A recently published
study showed that there were no differences in score for
quality of life among patients with colon cancer, rand-
omized to follow-up by GPs or specialists [31]. However,
this study is based upon follow-up procedures that differ
from those used in Norway (e.g. no regular radiological
procedures), and there is no cost-effectiveness analysis. To
our knowledge this is the first study addressing this prob-
lem. According to a Cochrane review, further research is
needed [7]. Studies addressing follow-up of other cancer
types by GPs have been performed, indicating for example
that breast cancer patients can be safely followed up by
their family physician without any concerns related to
clinical outcome or health-related quality of life [32].
Recent studies have indicated that the GP has a place in
the follow-up of many patients with cancer, also in the
initial phase after treatment [33]. Patients trust their GP to
provide competent care, especially when they have more
complex health care needs on top of their cancer [34-36].
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